<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826798</url>
  </required_header>
  <id_info>
    <org_study_id>VBI-1501</org_study_id>
    <nct_id>NCT02826798</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults</brief_title>
  <official_title>A Phase 1 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Candidate Human Cytomegalovirus Vaccine (VBI-1501) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VBI Vaccines Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trial Data Services, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VBI Vaccines Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and effectiveness of four different doses
      of cytomegalovirus vaccines in healthy adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to assess safety and immunogenicity of four dose formulations of
      cytomegalovirus (CMV) vaccine (0.5 μg gB content with aluminum phosphate (alum), 1.0 μg
      glycoprotein B (gB) content with alum, 2.0 μg gB content with alum, or 1.0 μg gB content
      (without alum) as compared with placebo in approximately 125 healthy CMV-seronegative
      volunteer participants between 18 and 40 years of age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2016</start_date>
  <completion_date type="Actual">August 24, 2017</completion_date>
  <primary_completion_date type="Actual">September 15, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events (AEs) from first injection to Day 336 or early withdrawal (EW), six months post Dose 3 in all participants, in all groups.</measure>
    <time_frame>From first injection to Day 336 or EW, six months post Dose 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints will include antibody binding titers and avidity measurement directed against the gB component of the vaccine, as well as neutralizing antibody titers against CMV infection of fibroblast and epithelial cells.</measure>
    <time_frame>From first injection to Day 336 or EW, six months post Dose 3</time_frame>
    <description>Comparisons will be made between vaccine groups, as well as with the CMV seropositive (naturally infected, unvaccinated) controls.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>VBI-1501A: 0.5µg with adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VBI-1501A: 1.0µg with adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VBI-1501A: 2.0 µg with adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VBI-1501: 1.0µg without adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Buffer/sucrose used for VBI-1501 suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VBI-1501A</intervention_name>
    <description>VBI-1501A: 0.5 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168</description>
    <arm_group_label>VBI-1501A: 0.5µg with adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VBI-1501A</intervention_name>
    <description>VBI-1501A: 1.0 μg with alum with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168</description>
    <arm_group_label>VBI-1501A: 1.0µg with adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VBI-1501A</intervention_name>
    <description>VBI-1501A: 2.0 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168</description>
    <arm_group_label>VBI-1501A: 2.0 µg with adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VBI-1501</intervention_name>
    <description>VBI-1501: 1.0 μg without alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168</description>
    <arm_group_label>VBI-1501: 1.0µg without adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>buffer/sucrose used for VBI-1501 suspension- administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Generally healthy adult female and male 18 to 40 years of age, inclusive;

          2. Serologically confirmed to be CMV seronegative at screening;

          3. Female volunteers must agree to use an adequate contraception method as deemed
             appropriate by the investigator

          4. Sign an informed consent document indicating understanding of the purpose and
             procedures required for the study and willingness to participate in the study

        Exclusion Criteria:

          1. History of or current clinically significant medical illness or any other illness that
             in the opinion of the investigator interferes with the interpretation of the study
             results

          2. Clinically significant abnormal physical examination, vital signs, or clinically
             significant abnormal values for hematology, clinical chemistry or urinalysis at
             screening as determined by the investigator

          3. Previous receipt of any cytomegalovirus vaccine

          4. History of allergic reactions or anaphylactic reaction to any vaccine component

          5. Pregnant or breastfeeding or plans to conceive from two weeks before the study start
             through six months after the last dose of study vaccine

          6. Known or suspected impairment of immunological function, including but not limited to
             autoimmune diseases, splenectomy, or HIV/AIDS

          7. Chronic administration (defined as more than 14 days in total) of immune-suppressive
             or other immune-modifying drug with six months prior to the product dose (for
             corticosteroids, this is defined as prednisone ≥20 mg/day or equivalent). Inhaled and
             topical steroids are allowed

          8. Participation in another clinical study within 30 days or plans to participate in
             another treatment based clinical study during the conduct of the present study

          9. Any skin abnormality or tattoo that would limit post-vaccination injection site
             assessment

         10. Any history of cancer requiring chemotherapy or radiation within 5 years of
             randomization or current disease

         11. Are family members of study center staff
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Langley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IWK Health Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vaccine Evaluation Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canadian Center for Vaccinology; IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre - Vaccine Study</name>
      <address>
        <city>Pierrefonds</city>
        <state>Quebec</state>
        <zip>H9H 4Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML, Best AM. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis. 1995 Jan;171(1):26-32. Erratum in: J Infect Dis 1995 Apr;171(4):1080.</citation>
    <PMID>7798679</PMID>
  </reference>
  <reference>
    <citation>Adler SP. Human CMV vaccine trials: what if CMV caused a rash? J Clin Virol. 2008 Mar;41(3):231-6. Epub 2007 Dec 21. Review.</citation>
    <PMID>18096431</PMID>
  </reference>
  <reference>
    <citation>Axelsson F, Adler SP, Lamarre A, Ohlin M. Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines. Vaccine. 2007 Dec 21;26(1):41-6. Epub 2007 Nov 9.</citation>
    <PMID>18063447</PMID>
  </reference>
  <reference>
    <citation>Baylor NW, Egan W, Richman P. Aluminum salts in vaccines--US perspective. Vaccine. 2002 May 31;20 Suppl 3:S18-23. Review. Erratum in: Vaccine. 2002 Sep 10;20(27-28):3428.</citation>
    <PMID>12184360</PMID>
  </reference>
  <reference>
    <citation>Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S, Benedicenti F, Vallanti G, Biasco L, Leo S, Kabbara N, Zanetti G, Rizzo WB, Mehta NA, Cicalese MP, Casiraghi M, Boelens JJ, Del Carro U, Dow DJ, Schmidt M, Assanelli A, Neduva V, Di Serio C, Stupka E, Gardner J, von Kalle C, Bordignon C, Ciceri F, Rovelli A, Roncarolo MG, Aiuti A, Sessa M, Naldini L. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013 Aug 23;341(6148):1233158. doi: 10.1126/science.1233158. Epub 2013 Jul 11.</citation>
    <PMID>23845948</PMID>
  </reference>
  <reference>
    <citation>FDA Guidance for industry (Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical studies, September 2007. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf.</citation>
  </reference>
  <reference>
    <citation>Fishman JA, Emery V, Freeman R, Pascual M, Rostaing L, Schlitt HJ, Sgarabotto D, Torre-Cisneros J, Uknis ME. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant. 2007 Mar-Apr;21(2):149-58. Review.</citation>
    <PMID>17425738</PMID>
  </reference>
  <reference>
    <citation>Fu TM, Wang D, Freed DC, Tang A, Li F, He X, Cole S, Dubey S, Finnefrock AC, ter Meulen J, Shiver JW, Casimiro DR. Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine. 2012 Dec 14;30(52):7469-74. doi: 10.1016/j.vaccine.2012.10.053. Epub 2012 Oct 26.</citation>
    <PMID>23107592</PMID>
  </reference>
  <reference>
    <citation>Gordon EM, Levy JP, Reed RA, Petchpud WN, Liu L, Wendler CB, Hall FL. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ. Int J Oncol. 2008 Oct;33(4):665-75.</citation>
    <PMID>18813779</PMID>
  </reference>
  <reference>
    <citation>Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RS, Emery VC, Burroughs AK. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011 Apr 9;377(9773):1256-63. doi: 10.1016/S0140-6736(11)60136-0.</citation>
    <PMID>21481708</PMID>
  </reference>
  <reference>
    <citation>Hacein-Bey-Abina S, Pai SY, Gaspar HB, Armant M, Berry CC, Blanche S, Bleesing J, Blondeau J, de Boer H, Buckland KF, Caccavelli L, Cros G, De Oliveira S, Fernández KS, Guo D, Harris CE, Hopkins G, Lehmann LE, Lim A, London WB, van der Loo JC, Malani N, Male F, Malik P, Marinovic MA, McNicol AM, Moshous D, Neven B, Oleastro M, Picard C, Ritz J, Rivat C, Schambach A, Shaw KL, Sherman EA, Silberstein LE, Six E, Touzot F, Tsytsykova A, Xu-Bayford J, Baum C, Bushman FD, Fischer A, Kohn DB, Filipovich AH, Notarangelo LD, Cavazzana M, Williams DA, Thrasher AJ. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med. 2014 Oct 9;371(15):1407-17. doi: 10.1056/NEJMoa1404588.</citation>
    <PMID>25295500</PMID>
  </reference>
  <reference>
    <citation>Institute of Medicine (US) Committee to Study Priorities for Vaccine Development; Stratton KR, Durch JS, Lawrence RS, editors. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington (DC): National Academies Press (US); 2000.</citation>
    <PMID>25121214</PMID>
  </reference>
  <reference>
    <citation>Loomis RJ, Lilja AE, Monroe J, Balabanis KA, Brito LA, Palladino G, Franti M, Mandl CW, Barnett SW, Mason PW. Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine. 2013 Jan 30;31(6):919-26. doi: 10.1016/j.vaccine.2012.12.009. Epub 2012 Dec 14.</citation>
    <PMID>23246547</PMID>
  </reference>
  <reference>
    <citation>Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, Gerna G, Sallusto F, Lanzavecchia A. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol. 2010 Jan;84(2):1005-13. doi: 10.1128/JVI.01809-09. Epub 2009 Nov 4.</citation>
    <PMID>19889756</PMID>
  </reference>
  <reference>
    <citation>15. Paneque-Quevedo AA. Inorganic compounds as vaccine adjuvants. Biotecnología Aplicada. 2013;30:250-256.</citation>
  </reference>
  <reference>
    <citation>Pass RF, Duliegè AM, Boppana S, Sekulovich R, Percell S, Britt W, Burke RL. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis. 1999 Oct;180(4):970-5.</citation>
    <PMID>10479120</PMID>
  </reference>
  <reference>
    <citation>Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009 Mar 19;360(12):1191-9. doi: 10.1056/NEJMoa0804749.</citation>
    <PMID>19297572</PMID>
  </reference>
  <reference>
    <citation>Plotkin SA. Is there a formula for an effective CMV vaccine? J Clin Virol. 2002 Aug;25 Suppl 2:S13-21. Review.</citation>
    <PMID>12361753</PMID>
  </reference>
  <reference>
    <citation>Zydek M, Petitt M, Fang-Hoover J, Adler B, Kauvar LM, Pereira L, Tabata T. HCMV infection of human trophoblast progenitor cells of the placenta is neutralized by a human monoclonal antibody to glycoprotein B and not by antibodies to the pentamer complex. Viruses. 2014 Mar 19;6(3):1346-64. doi: 10.3390/v6031346.</citation>
    <PMID>24651029</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>July 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VBI-1501A</keyword>
  <keyword>VBI-1501</keyword>
  <keyword>prophylactic vaccine</keyword>
  <keyword>virus diseases</keyword>
  <keyword>cytomegalovirus</keyword>
  <keyword>CMV</keyword>
  <keyword>cytomegalovirus infections</keyword>
  <keyword>cytomegalovirus vaccines</keyword>
  <keyword>Herpesviridae Infections</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Human Herpesvirus 5</keyword>
  <keyword>HHV5</keyword>
  <keyword>Vaccines, virus-like particle</keyword>
  <keyword>VLP</keyword>
  <keyword>enveloped virus-like particle</keyword>
  <keyword>eVLP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

